Amgen (NASDAQ: AMGN) is doing something unusual in 2025. Here's why this $150 billion pharmaceutical powerhouse deserves a ...

Federal jurors in Delaware found that Amgen violated antitrust laws by bundling its cholesterol treatment with substantial ...

Zacks Research just turned up the heat on Amgen, raising its FY2025 earnings per share estimate to $20.66 from $20.16. Amgen ...

The Federal Court has granted Alexion a declaration of infringement and an injunction preventing Amgen from manufacturing, ...

Friberg currently works at BioMarin Pharmaceutical, Inc., as Executive VP, Chief Research & Development Officer from 2024. Dr. Friberg also formerly worked at Amgen, Inc., as Vice President-Global ...